Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $3.64

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price gapped up prior to trading on Friday . The stock had previously closed at $3.64, but opened at $3.80. Autolus Therapeutics shares last traded at $3.59, with a volume of 24,800 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a research note on Monday, June 3rd. Needham & Company LLC reiterated a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a research note on Monday, June 17th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Autolus Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $8.70.

Autolus Therapeutics Stock Up 0.3 %

The stock has a 50-day moving average price of $4.08 and a 200 day moving average price of $4.91. The firm has a market capitalization of $971.03 million, a price-to-earnings ratio of -2.99 and a beta of 2.11.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). As a group, equities analysts forecast that Autolus Therapeutics plc will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Daiwa Securities Group Inc. increased its position in Autolus Therapeutics by 2,659.7% during the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after buying an additional 15,293 shares during the period. Bayesian Capital Management LP acquired a new position in Autolus Therapeutics during the first quarter worth about $100,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Autolus Therapeutics during the 1st quarter valued at approximately $108,000. SG Americas Securities LLC purchased a new stake in shares of Autolus Therapeutics during the 1st quarter worth approximately $127,000. Finally, EntryPoint Capital LLC raised its holdings in Autolus Therapeutics by 113.6% during the first quarter. EntryPoint Capital LLC now owns 21,540 shares of the company’s stock worth $137,000 after purchasing an additional 11,456 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.